INNOVATION IN ONCOLOGY: new drugs and the impact of artificial intelligence
Not eligible for ESCO credits
12.11.2025 - 13.11.2025
Milan, Italy
CONFERENCE
Description
Innovation in Oncology: new drugs and the impact of artificial intelligence
The FGB-FM-ESO Joint International Conference 2025 brings together world-leading experts in oncology to explore cutting-edge developments in cancer therapeutics and the transformative potential of artificial intelligence in clinical practice. This two-day conference will foster collaboration between clinicians and researchers, promoting knowledge exchange and innovation in cancer care. Besides, the conference hosts the “Gianni Bonadonna Prize” for young investigators in the field of innovative therapies in oncology. This year is the 10th Anniversary since the passing of Gianni Bonadonna, and this award will be an important occasion to honour one of the founding fathers of modern oncology.
Conference Aims:
- To showcase breakthrough developments in cancer therapeutics, with a focus on novel drug delivery systems and targeted therapies
- To explore the integration of artificial intelligence in oncology, from diagnosis to treatment selection
- To facilitate knowledge transfer between academic research and clinical practice
- To promote collaboration between established researchers and emerging talent in the field
- To provide a platform for discussing practical implementation challenges and solutions
Download here the Conference Brochure
Information
OFFICIAL LANGUAGE
The official language will be English. No translation will be available.
VENUE
The Convention will be held at Fondazione Prada, Godard Cinema, Largo Isarco 2 - Milan, Italy
CME ACCREDITATION
The conference has been accredited by the European Accreditation Council for Continuing Medical Education (EACCME®) for 8.5 European CME credits (ECMEC®s).
PARTICIPATION
Attendance is limited to 180 participants and admittance is on a first come, first served basis.
The registration grants you:
- Free registration
- Meals according to the programme
It does not cover travel costs, accommodation and extra expenses, these should be organized and paid by the participant. Accompanying persons will not be accepted.
INSURANCE
The organisers bear no responsibility for untoward events in relation to the participation in the event. Participants are advised to take out their own personal and travel insurance coverage.
ORGANISING SECRETARIAT
European School of Oncology
m: +39 3371061207
European School of Oncology
m: +39 3371061207
Programme
12 November | ||
| 13:00 | Registration and networking | |
| 14:00 | Welcome and introduction | |
| 14:15 | SESSION 1: EMERGING PARADIGMS IN DRUG DEVELOPMENT | |
| 14:15 | Next-Generation Antibody-Drug Conjugates: Design Principles and Clinical Applications Raffaele Colombo, CA | |
| 14:45 | Emerging Paradigms in Cancer Immunotherapy Giampaolo Bianchini, IT | |
| 15:15 | New Frontiers in Endocrine Therapy for Breast Cancer Rinath Jeselsohn, US | |
| 15:45 | T Cell Engineering for Solid Tumors: Challenges and Opportunities Chiara Bonini, IT | |
| 16:15 | Discussion | |
| 16:45 | GIANNI BONADONNA PRIZE 2025: THE AWARD CEREMONY | |
| 16:45 | Presentation of the winner project | |
13 November | ||
| 9:00 | SESSION 2: DIAGNOSTIC REVOLUTION IN ONCOLOGY AND ROLE OF ARTIFICIAL INTELLIGENCE | |
| 9:00 | Clinical utility of ctDNA for treatment monitoring and early detection of resistance mechanisms in metastatic breast cancer Isaac Garcia-Murillas, UK | |
| 9:30 | Radiomics: Transforming Imaging Data into Precision Oncology Irène Buvat, FR | |
| 10:00 | Utilizing Computational Pathology to Discover Biomarkers for Predicting Response in breast and ovarian cancer Sara Pires de Oliveira, NL | |
| 10:30 | Breakthrough technologies: single-cell and spatially resolved Lubna Ahmad, UK | |
| 11:00 | Coffee Break | |
| 11:30 | Biomarker development and clinical application: breast cancer as a model Lajos Pusztai, US | |
| 12:00 | From cloud to bedside: Responsible AI predictive models in healthcare Carlo Tacchetti, IT | |
| 12:30 | Critical view of AI in Oncology Ian Tannock, CA | |
| 13:00 | Discussion | |
| 13:30 | Lunch | |
| 14:30 | SESSION 3: NEW HORIZONS IN ONCOLOGY DRUG DEVELOPMENT | |
| 14:30 | Revolutionizing Dose Optimization, Efficacy Evaluation, and Tumor-Agnostic Methods in Early-Phase Clinical Trials Vivek Subbiah, US | |
| 15:00 | Post-Approval Dose Optimization to Improve the Therapeutic Index and Reduce Costs Mark J. Ratain, US | |
| 15:30 | Tumor adaptive responses and rational development of drug combinations Diego Tosi, FR | |
| 16:00 | Discussion | |
| 16:30 | Conclusions | |
Faculty
Lubna Ahmad, CRUK, Cancer Research UK Cambridge Centre, Cambridge, UK
Giampaolo Bianchini, Ospedale San Raffaele, Dept. of Medical Oncology - O.U. Medicine 1Q-A, Milano, IT
Chiara Bonini, IRCCS Ospedale San Raffaele, Experimental hematology, Milano, IT
Irène Buvat, Institut Curie Paris, Director Laboratory of Translational Imaging in Oncology, Paris, FR
Raffaele Colombo, Zymeworks Inc, ADC Therapeutic Development, Vancouver, CA
Isaac Garcia-Murillas, The Institute of Cancer Research, Molecular Oncology, London, UK
Hugo Horlings, Netherlands Cancer Institute, Netherlands Cancer Institute, Amsterdam, NL
Rinath Jeselsohn, Dana-Farber Cancer Institute, Dana-Farber Cancer Institute, Boston, US
Lajos Pusztai, Yale Cancer Center, Scientific Co-Director of the Center for Breast Cancer, New Haven, US
Mark J. Ratain, Cancer Research Center, The University of Chicago, Dept. of Medicine, Chicago, US
Vivek Subbiah, Sarah Cannon Research Institute (SCRI), Sarah Cannon Research Institute (SCRI), Nashville, Tennessee, US
Carlo Tacchetti, IRCCS Ospedale San Raffaele, IRCCS Ospedale San Raffaele, Milano, IT
Ian Tannock, Toronto, CA
Diego Tosi, Cancer Institute of Montpellier (ICM), Oncology, Montpellier, FR
Registration
Attendance is limited to 180 participants and admittance is on a first come, first served basis.
HOW TO REGISTER
Interested PARTICIPANTS should register online (at the top of this page).
Once registered, participants will receive a confirmation email with details